Home › Funds › Ranger Investment Management, L.P. › PTGX
Ranger Investment Management, L.P. position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
Ranger Investment Management, L.P. reported holding 82,362 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$11.6M, representing 1.09% of its reported portfolio and ranking #36 among its reported holdings. Ranger Investment Management, L.P. first reported this position in Q3 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Ranger Investment Management, L.P.'s PTGX position evolved
Ranger Investment Management, L.P. first disclosed a stake in PTGX in Q3 2026 at 82,362 shares (US$11.6M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 82.36K | $11.60M | New |
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 51 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $620.40M · Q2 2026
- JOHNSON & JOHNSON 2.45M sh · $345.07M · Q3 2026
- Woodline Partners LP 1.41M sh · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- ADAR1 Capital Management, LLC 960.86K sh · $117.78M · Q2 2026
- Hood River Capital Management LLC 882.74K sh · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K sh · $35.55M · Q2 2026
- NEXTBio Capital Management LP 219.33K sh · $30.90M · Q3 2026
- Eagle Health Investments LP 248.32K sh · $30.44M · Q2 2026
More on Ranger Investment Management, L.P.
FAQ
How long has Ranger Investment Management, L.P. held PTGX?
Ranger Investment Management, L.P. has disclosed PTGX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Ranger Investment Management, L.P.'s current position in PTGX?
As of Q3 2026, Ranger Investment Management, L.P. holds 82.36K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $11.60M, representing 1.09% of its reported portfolio and ranking #36.
Has Ranger Investment Management, L.P. been buying or selling PTGX?
In the latest 13F filing (Q3 2026), Ranger Investment Management, L.P. newly opened its position in PTGX.
Which other funds hold PTGX?
Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.